De Novo device
Kerasave
Al.Chi.Mi.A. S.R.L · Corneal Storage Media With Preservatives Including Anti-Fungal (QCW, Class II) · First FDA decision May 2, 2022, newest May 2, 2022Keratoconus and corneal disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
0
Naming "Kerasave"
MAUDE reports
0
Brand "Kerasave", since 2015
PubMed studies
7
Mentioning "Kerasave"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Kerasave
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- KerasaveNew device typeDe Novo
DEN200063 · Decided May 2, 2022 · 578 days after receipt
Device type: Corneal Storage Media With Preservatives Including Anti-Fungal (QCW) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Kerasave", any status and sponsor, newest update first.
No registered device study names "Kerasave".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Kerasave", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QCW
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Kerasave"[tiab]. The summary above synthesizes these.
- A new storage medium containing amphotericin B versus Optisol-GS for preservation of human donor corneas.
Mistò R, Giurgola L, Pateri F, et al. · Br J Ophthalmol · 2022
- Comparative Analysis of Endothelial Cell Density and Central Thickness of Corneas Used for Endothelial Keratoplasty Procedures Using Various Storage Solutions.
Ramini A, Titus MS, Sawant OB · Cornea · 2025Comparative Study
- Killing efficacy of a new hypothermic corneal storage medium against the micro-organisms frequently found in human donor cornea intended for transplantation.
Giurgola L, Gatto C, Honisch C, et al. · BMJ Open Ophthalmol · 2021
- Antimycotic Efficacy and Safety of a New Cold Corneal Storage Medium by Time-Kill and Toxicity Studies.
Giurgola L, Gatto C, Parel JM, et al. · Cornea · 2019
- Performance of New Hypothermic Corneal Storage Media With an Antimycotic Tablet in Comparison to Traditional Hypothermic Media During Simulated Eye Bank Processing.
Perry I, Peterson K, Tóthová JD, et al. · Cornea · 2020Comparative Study
- 19ߕKilling efficacy of a new hypothermic corneal storage medium Kerasave at 4°C against nine micro- organisms frequently found in donor corneas.
MSc LG, Tothova JD, MSc CG, et al. · BMJ Open Ophthalmol · 2022
- Prospective In Vitro Comparison of Kerasave and Optisol-GS Corneal Storage Solutions.
Tran KD, Ellison M, Straiko MMW, et al. · Cornea · 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.